Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA ‐8010 in healthy subjects: First‐in‐human phase I study
Pharmacology Research & Perspectives · 2023-02 · 11 (1)
DOI: 10.1002/prp2.1040 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 03.02.2023. Verfasst von Dae Young Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dong-A ST Research Center, Giheung-gu, South Korea. Hauptthemen laut MEDLINE: Dizziness. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study assessed the safety, tolerability, and pharmacokinetics of single and multiple oral doses of DA‐8010, a muscarinic M 3 receptor antagonist, in healthy subjects. This was a randomized, double‐blind, placebo‐controlled, ascending single (Part A: 1, 2.5, 5, 20, and 40 mg QD fasted and 10 mg QD fasted and fed) and multiple doses (Part B: 5, 10, and 20 mg QD from Days 1 to 7 fasted), sequential‐group study. Safety data were analyzed descriptively, time to maximum plasma concentration ( t max ) nonparametrically, and pharmacokinetic parameters using power and mixed models and ANOVA. Of 109 subjects randomized (Part A = 69 and Part B = 40; each part consisted a female group), 31 (44.9%) in Part A and 29 (72.5%) in Part B experienced treatment‐emergent adverse events (TEAEs) in a dose‐related manner. Common drug‐related TEAEs in Part A and B were dizziness (8.7% and 15.0%), headache (5.8% and 12.5%) and blurred vision (8.7% and 20%). One male (20 mg) and one female (10 mg) from Part B discontinued the study due to a confusional state, and nausea and vomiting. Irrespective of sex, DA‐8010 was steadily absorbed following single and multiple doses in the fasted state with increased systemic exposure in a dose‐proportional manner with maximum plasma concentration occurring at a median t max between 4.0 and 6.0 h. A high‐fat meal increased systemic exposure. DA‐8010 was safe, well tolerated, and well absorbed at lower doses and moderately tolerated at higher doses without any notable effects of food and sex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dong-A ST Research Center, Giheung-gu, South Korea.
- Dong-A ST HQ, Seoul, South Korea.
- Labcorp Drug Development, Clinical Research Unit Limited, Springfield House, West Yorkshire, UK.
ORCID-Profile: Ashley Brooks
Zitieren
APA
Lee, D. Y., Lee, M. J., Ryu, C., Lee, H., & Brooks, A. (2023). Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA ‐8010 in healthy subjects: First‐in‐human phase I study. Pharmacology Research & Perspectives, 11(1). https://doi.org/10.1002/prp2.1040
Vancouver
Lee DY, Lee MJ, Ryu C, Lee H, Brooks A. Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA ‐8010 in healthy subjects: First‐in‐human phase I study. Pharmacology Research & Perspectives. 2023;11(1). doi:10.1002/prp2.1040
BibTeX
@article{Lee2023,
author = {Lee, Dae Young and Lee, Min Jung and Ryu, Chaelim and Lee, Heewon and Brooks, Ashley},
title = {Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA ‐8010 in healthy subjects: First‐in‐human phase I study},
journal = {Pharmacology Research & Perspectives},
year = {2023},
volume = {11},
number = {1},
doi = {10.1002/prp2.1040}
}
EUVIMED